Interactions between cardiology and oncology drugs in precision cardio-oncology. Clin Sci (Lond) 2021 Jun 11;135(11):1333-1351
Date
06/03/2021Pubmed ID
34076246Pubmed Central ID
PMC8984624DOI
10.1042/CS20200309Scopus ID
2-s2.0-85107397120 (requires institutional sign-in at Scopus site) 22 CitationsAbstract
Recent advances in treatment have transformed the management of cancer. Despite these advances, cardiovascular disease remains a leading cause of death in cancer survivors. Cardio-oncology has recently evolved as a subspecialty to prevent, diagnose, and manage cardiovascular side effects of antineoplastic therapy. An emphasis on optimal management of comorbidities and close attention to drug interactions are important in cardio-oncologic care. With interdisciplinary collaboration among oncologists, cardiologists, and pharmacists, there is potential to prevent and reduce drug-related toxicities of treatments. The cytochrome P450 (CYP450) family of enzymes and the P-glycoprotein (P-g) transporter play a crucial role in drug metabolism and drug resistance. Here we discuss the role of CYP450 and P-g in drug interactions in the field of cardio-oncology, provide an overview of the cardiotoxicity of a spectrum of cancer agents, highlight the role of precision medicine, and encourage a multidisciplinary treatment approach for patients with cancer.
Author List
Kamaraju S, Mohan M, Zaharova S, Wallace B, McGraw J, Lokken J, Tierney J, Weil E, Fatunde O, Brown SAAuthors
Sailaja Kamaraju MS, MBBS Professor in the Medicine department at Medical College of WisconsinSvetlana Zaharova PhD, MSN Assistant Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AgedAntineoplastic Agents
Cardiotoxicity
Cardiovascular Diseases
Female
Humans
Medical Oncology
Neoplasms
Precision Medicine
